Jay Dorsey, MD
Enriched profileAssociate Professor of Radiation Oncology · University of Pennsylvania
Jay Dorsey is Associate Professor of Radiation Oncology at University of Pennsylvania. ClinicalTrials.gov lists 3 registered studies with this person as an investigator.
Data verified 25 Oct 2026
Overview
Updated 28 Oct 2026
Jay Fitzgerald Dorsey, MD, PHD, is Associate Professor of Radiation Oncology at University of Pennsylvania (Penn Medicine, Department of Radiation Oncology). The public record shows 180 publications with 5,334 citations (h-index 38), centered on Central Nervous System Neoplasms, Nervous System Neoplasms. It also documents an investigator role on 3 registered clinical trials, industry payments reported by 1 companies, 6 NIH-funded awards (2011–2026).
- Top research focus: Central Nervous System Neoplasms
- 3 registered trials on ClinicalTrials.gov
- Open Payments reporting from 1 companies
Generated from the cited public record · current as of 28 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 28 Oct 2026
Listed as an investigator on 3 registered studies on ClinicalTrials.gov. The most recent:
- Healthy Human Control Blood Collection for Validation of Biomarker Assay
Sponsor: Abramson Cancer Center at Penn Medicine
- The Radiation Oncology Registry and Biosample Repository
Sponsor: Abramson Cancer Center at Penn Medicine
- Nelfinavir Mesylate, Radiation Therapy, and Temozolomide in Treating Patients With Glioblastoma Multiforme
Sponsor: Abramson Cancer Center at Penn Medicine
Industry payments
Updated 28 Oct 2026
1 company reported payments to CMS in program years 2025–2025. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year20251 payment
NIH funding
Updated 28 Oct 2026
6 NIH research awards on record, funded 2011–2026 per NIH RePORTER. The latest:
- FLASH-CAR-T radioimmunotherapy in pediatric brain tumor
University of Pennsylvania
FY2026$618,063R01CA311313 - Summer Undergraduate Program to Educate Radiation Scientists (SUPERS)
University of Pennsylvania
FY2026$279,071R25CA140116 - Summer Undergraduate Program to Educate Radiation Scientists (SUPERS)
University of Pennsylvania
FY2025$260,480R25CA140116
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Cell plasticity, senescence, and quiescence in cancer stem cells: Biological and therapeutic implications
Pharmacology & Therapeutics
2021 - Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40
Nature Communications
2021 - Novel Treatment for Glioblastoma Delivered by a Radiation Responsive and Radiopaque Hydrogel
ACS Biomaterials Science & Engineering
2021
Background & recognition
Updated 28 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →xrt.upenn.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancer.pennmedicine.org ↗
Editorial & leadership roles
journal and society appointments- Standing member
NIH K99/R00 transition to independence study section
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →med.upenn.edu ↗ - Co-Leader
RadOnc Translational Center of Excellence, Abramson Cancer Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →xrt.upenn.edu ↗ - Director
SUPERS@PENN undergraduate research program
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →xrt.upenn.edu ↗
Secondary affiliations
appointments beyond the home institution- Co-Founder
Liquid Biotech USA (per Crunchbase; listing dated, shows assistant professor title)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →crunchbase.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Carl June, MD
University of Pennsylvania
Raquel Gur, MD
University of Pennsylvania
Howard Herrmann, MD
University of Pennsylvania
Robert Vonderheide, MD
University of Pennsylvania
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center